6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Subscribers Only

It's a good one, too.

This digital health research is for Exits & Outcomes subscribers only. Subscribe now to get the weekly newsletter. Enter your email below to subscribe today!

Newsletters

ACCESS Model’s shockingly low payments. DMHT Rx count.

2.13.26

7 min. Read

HLTH acquisition price. Estimating Pomelo Care pricing, revenue, and more

1.09.26

7 min. Read

CMS to pay for ADHD DTx. More PFS notes. Two FDA De Novos.

11.07.25

6 min. Read

Pricing for Sword Health, Hinge Health, Joint Academy in the UK.

10.31.25

7 min. Read

Spring, Slingshot AI, Click and others write FDA about GenAI. Big Health board departs.

10.24.25

7 min. Read

Cigna clarifies new non-coverage policy for PDTs. Bevel $10M. FDA GenAI comments.

10.17.25

5 min. Read

Revisiting E&O scoops, pricing intel, revenue finds

10.10.25

7 min. Read

Big Health’s 2024 revenue shrinks. 2025: Runway worries.

9.26.25

5 min. Read

Kavira Health pricing. What did Swing Therapeutics buy? PFS Comments.

9.18.25

7 min. Read

Cerebral’s $25M M&A. Amazon-Fay. Oshi growth numbers.

9.12.25

4 min. Read

Scoop: Amwell in talks to buy Omada

Welcome to E&O.

Subscribers Only

E&O's weekly newsletter.